Economic consequences of the implementation of national screening program for chronic HCV infection.
Conclusions: Targeted testing among adults between 39 and 64 years with anti-HCV antibody once per their life in Bulgaria could be considered as cost-effective and provides benefits both for the paying institutions and the patients.
PMID: 31514552 [PubMed - as supplied by publisher]
Source: Expert Review of Pharmacoeconomics and Outcomes Research - Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research
More News: Bulgaria Health | Health Management | Liver | Liver Disease | Study | Urology & Nephrology